Shattuck Labs Inc at TD Cowen Healthcare Conference Transcript
All right. Welcome to the 46th annual TD Cowen Healthcare Conference. I'm [Mark Frahm] from the biotech team here at TD Cowan. First up this morning, we are really pleased to have with us, from Shattuck Labs, Taylor Schreiber, the CEO.
He's going to tell us the way we're going to run this is he's going to run through a few, slides and prepared remarks, talking about their program in IBD targeting DR3, and then, we'll do maybe the back half or so of the presentation slot, as Q&A. And so I'll rejoin for that but with that, I'll turn it over to Taylor.
Great. Thank you, Mark. Sorry to keep everybody waiting. So as Mark said, Shattuck is, focused on a DR3 blocking antibody. DR3 is the receptor for TL1A. These are my forward-looking statements.
Just to set the stage for anybody who's not already familiar, like, people are pretty familiar with the TL1A space today.
But the reason that folks have been so excited about this axis and the reason why
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
